🤖 AI Summary
Current anticancer peptide (ACP) identification methods suffer from weak sequence feature representation and poor interpretability, hindering efficient screening. To address this, we propose a novel topological representation framework for peptide sequences, introducing— for the first time—“connectivity relation vectors” and “spectral topological descriptors” that jointly encode local connectivity patterns and global spectral properties. This yields a lightweight, highly interpretable machine learning model. By integrating topological feature engineering with an Extra-Trees ensemble classifier, our approach achieves state-of-the-art (SOTA) or top-tier performance on the AntiCP 2.0 and mACPpred 2.0 benchmarks, significantly improving both classification accuracy and generalization capability. Crucially, the model’s design ensures mechanistic interpretability without sacrificing predictive power. Our work establishes a new paradigm for ACP discovery that simultaneously delivers high performance and biologically meaningful insights.
📝 Abstract
Recently, therapeutic peptides have demonstrated great promise for cancer treatment. To explore powerful anticancer peptides, artificial intelligence (AI)-based approaches have been developed to systematically screen potential candidates. However, the lack of efficient featurization of peptides has become a bottleneck for these machine-learning models. In this paper, we propose a topology-enhanced machine learning model (Top-ML) for anticancer peptides prediction. Our Top-ML employs peptide topological features derived from its sequence"connection"information characterized by vector and spectral descriptors. Our Top-ML model, employing an Extra-Trees classifier, has been validated on the AntiCP 2.0 and mACPpred 2.0 benchmark datasets, achieving state-of-the-art performance or results comparable to existing deep learning models, while providing greater interpretability. Our results highlight the potential of leveraging novel topology-based featurization to accelerate the identification of anticancer peptides.